

NIH Public Access

Author Manuscript

J Am Chem Soc. Author manuscript; available in PMC 2014 December 26.

Published in final edited form as:

J Am Chem Soc. 2013 December 26; 135(51): 19079–19082. doi:10.1021/ja4105792.

Identification of a Selective Polymerase Enables Detection of N⁶methyladenosine in RNA

Emily M. Harcourt¹, Thomas Ehrenschwender¹, Pedro J. Batista², Howard Y. Chang², and Eric T. Kool^{1,*}

¹Department of Chemistry, Stanford University, Stanford, California 94305

²Howard Hughes Medical Institute and Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305, USA

Abstract

 N^6 -methyladenosine (m⁶A) is the most abundant mRNA modification, and has important links to human health. While recent studies have successfully identified thousands of mammalian RNA transcripts containing the modification, it is extremely difficult to identify the exact location of any specific m⁶A. Here we have identified a polymerase with reverse transcriptase activity (from *Thermus thermophilus*) that is selective by up to 18-fold for incorporation of thymidine opposite unmodified A over m⁶A. We show that the enzyme can be used to locate and quantify m⁶A in synthetic RNAs by analysis of pausing bands, and have used the enzyme in tandem with a nonselective polymerase to locate the presence and position of m⁶A in high-abundance cellular RNAs. By this approach we demonstrate that the long-undetermined position of m⁶A in mammalian 28S rRNA is nucleotide 4190.

> In the quest to understand cellular function at the molecular level, the study of posttranscriptional modification of RNA is of vital interest. In particular, N⁶-methyladenosine (m⁶A, **1**) is a relatively abundant modification in the messenger RNA of higher eukaryotes and some viruses.¹ Although its discovery in mRNA occurred decades ago,² there has been renewed interest in m⁶A due to the finding that it acts as a substrate for fat mass and obesityassociated protein (FTO),³ an oxidative demethylase which has been linked to obesity and the regulation of homeostasis;^{4–6} and for AlkBH5, an oxidative demethylase in the same family.⁷

> Identifying the function of m⁶A modifications has proved challenging.^{8–12} Early work using enzymatic digestion and radiolabelling led to the discovery of the consensus sequence RAC (R=A or G) for m⁶A^{13–18} and the identification of specific modified sites in Rous Sarcoma Virus mRNA^{19–21} and in bovine prolactin mRNA.^{22,23} This research also showed that methylation at any particular site can be incomplete, with a methylation extent of 20–90% at one site. Modern RNA sequencing techniques have advanced our ability to identify transcripts modified by m⁶A. Using massively parallel sequencing and m⁶A-selective antibodies, two groups recently identified thousands of modified mRNAs and ncRNAs from mice and humans and confirmed the general consensus sequence of RRACU for the location of methylated adenines.^{24,25} After completion of the present work, Liu *et al.* reported a new

Corresponding Author: kool@stanford.edu.

Supporting Information. Experimental methods and materials, additional data, and characterization of synthetic intermediates. This material is available free of charge via the Internet at http://pubs.acs.org.

No competing financial interests have been declared.

method for detecting and quantifying m⁶A at a specific site using multiple enzymatic steps.²⁶ However, the ability to interrogate the methylation status of any specific adenine at nucleotide resolution, without painstaking digestion analysis, has remained elusive.



The ability to locate m⁶A modifications in RNAs at nucleotide resolution will no doubt aid in understanding their function. Polymerase enzymes offer a possible mechanism for locating modifications due to their sterically sensitive active sites. Notably, polymerase selectivity has previously been harnessed to detect m⁶A in DNA via single-molecule sequencing.²⁷ An early attempt at a related single-molecule sequencing technique for RNA has also been described,²⁸ but employed an enzyme with low selectivity (HIV-RT; see below), and will need further development before it is practical. Another class of DNAprocessing enzymes, ligases, can also be sensitive to structure, and Dai *et al.* describe a technique in which ligation of complementary DNAs occurs more favorably in the presence of A than m⁶A.²⁹ However, the conditions were tuned carefully for the specific reaction, and no attempt was made to detect m⁶A in an actual sample of cellular RNA.

We postulated that there might exist a polymerase enzyme with substantial selectivity against m^6A , and that such an enzyme might be harnessed for site-specific detection of the modification. We carried out a screen of enzymes with reverse transcriptase activity, monitoring their ability to extend a radiolabeled DNA primer by incorporating thymidine triphosphate (dTTP) opposite either A or m^6A in an RNA template (Figure 1). The data showed that only recombinant *Thermus thermophilus* DNA polymerase I (*Tth* DNA pol) showed strong selectivity (61% vs. 15% primer extension) among the enzymes tested. This DNA polymerase is known to act as a reverse transcriptase in the presence of Mn^{2+} .³⁰

Since *Tth* DNA pol showed selectivity in the context of one specific template sequence under one set of conditions, we tested if variations in temperature, time, and buffer composition might enhance selectivity (see Supporting Information (SI)). In particular, Mn^{2+} is known to decrease enzyme selectivity;³¹ however, we found that Mn^{2+} was required for reverse transcriptase activity in *Tth* DNA pol.

We next investigated whether this selectivity would extend to other sequence contexts. A 24mer template sequence was chosen from the 3' untranslated region (3'-UTR) of the *eef2* gene, which was found to be highly expressed and highly modified in mouse tissue and mouse embryonic stem cells.^{25,32} The template was synthesized containing either A or m⁶A, and the bases on either side of the A/m⁶A were varied systematically to allow a comparison of sequence context effects (see SI for details). In addition, several of the native sequence contexts in which m⁶A has been reported to occur were also synthesized. Single nucleotide

incorporation kinetics were determined for each sequence containing A and m⁶A using steady-state methods³³ (Table 1).

The RNA templates containing A show 4- to 18-fold better enzyme efficiency with *Tth* pol than the corresponding sequence containing m^6A . Overall, then, differences in context produce moderate to negligible differences in selectivity. For example, for T incorporation opposite unmodified A, the UAA sequence context is processed with higher efficiency than other sequences. Additionally, 5' G and 3' C both appear to decrease enzyme efficiency to a small degree. Most notably, the selectivity of the *Tth* polymerase in the consensus methylation site context (GAC) is 4 to 6.4-fold, thus supporting the notion that the enzyme's selectivity may be useful for identifying the most common occurrences of m^6A in naturally occurring RNAs.

Next we asked whether the *Tth* enzyme could be used in a quantitative sense, to evaluate the degree of methylation at a specific site. To test this, we mixed known ratios of m^6A -containing RNAs with their A-containing counterparts, and measured the yield of dTTP incorporation at a fixed timepoint. The percent extension of the primer in this RNA context was linearly proportional to the amount of m^6A present (Figure 2), suggesting that the polymerase can be used in quantitative evaluations of the extent of methylation at one position.

We proceeded to carry out experiments to test whether this enzyme could be employed in probing methylation in RNAs extracted from mammalian cells. Since the amount of RNA and its secondary structure are likely to affect primer extension efficiencies, we introduced two control strategies. The first of these involves the use of two simultaneous primers (one adjacent to the probed methylation site, and one nearby but adjacent to a nucleotide with known methylation status). Comparison of these two should account for the amount of a given RNA present in a sample. The second control makes use of the same primers with a non-selective enzyme, avian mye-loblastosis virus reverse transcriptase (AMV RT). AMV RT was selected because it showed consistent ratios relative to *Tth* DNA pol across a range of RNA concentrations. Insertion of T at a site of interest could then be compared both to the control site and to incorporation by a control nonselective enzyme.

Human ribosomal RNA is known to contain two m⁶A modifications, one at position 1832 in the 18S subunit, and one at position 4189 or 4190 in the 28S subunit.³⁴ Based on ratios to nearby unmodified bases after enzymatic digestion, these sites are reported to consist only of the modified base (100% m⁶A).^{35,36} Primers were designed to interrogate these three sites, as well as two other sites known to contain A (1781 in 18S; 4984 in 28S). Total RNA was extracted from 293T cells, and the RNAs probed with primer sets (see SI). As seen in Figure 3, results showed less than 20% incorporation of T by *Tth* DNA pol at the 1832 m⁶A site and the 4190 m⁶A site relative to controls, consistent with complete methylation in our quantitative experiments with synthetic RNAs. In contrast, we observed a high degree of incorporation (~120%) by *Tth* pol relative to AMV RT at the 4189 site. As a result, we can assign the previously-undetermined site of methylation in human 28S RNA as 4190 and not at the neighboring adenine at 4189.

Finally, we attempted to detect m^6A in a cellularly expressed messenger RNA (Figure 4). We chose a known site in the 3'-UTR of the bovine prolactin (bPRL) transcript.²³ This is the only precisely mapped m^6A site in a mammalian mRNA; native levels of modification are estimated to be ca. 20%, and this presents a challenging case for detection.²³ The 3'-UTR was cloned into a plasmid and overexpressed in 293T cells. Two primers were designed, one to detect the known modification site and one to detect a nearby adenosine (see SI). The putative m^6A site showed significantly lower incorporation than the nearby control A site.

As an additional control, we performed *in vitro* transcription of the *bPRL* transcript in the absence of m⁶A, allowing us to compare the primer incorporation at the site of interest when only A was present. At the high enzyme concentrations initially used, no difference was seen between the total cellular RNA and the *in vitro* transcribed RNA. Use of a lower enzyme concentration, however, did reveal a significant difference in the m⁶A:A ratio $(0.75\pm0.09 \text{ for IVT RNA vs. } 0.43\pm0.04 \text{ for total cellular RNA; all extension products were included in quantification}, confirming the presence of m⁶A in the mRNA expressed in 293T cells.$

In summary, we have characterized a commercially available polymerase that discriminates m^6A from A in all tested sequence contexts. We have used it to detect m^6A in abundant cellular RNAs. While further development is needed before this method is robust enough for detection and quantification of m^6A in lower abundance mRNAs, it seems likely that the inherent selectivity of this enzyme will prove useful in the development of future m^6A analysis techniques.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (GM068122) for support. EMH is supported by a Graduate Research Fellowship (DGE-1147470) from the NSF. TE is supported by a Postdoctoral Research Fellowship from the DAAD. PJB is the Kenneth G. and Elaine A. Langone Fellow of the Damon Runyon Cancer Research Foundation; HYC is an Early Career Scientist of Howard Hughes Medical Institute.

References

- Bokar, JA. The Biosynthesis and Functional Roles of Methylated Nucleosides in Eukaryotic mRNA. In: Grosjean, H., editor. Fine-tuning of RNA Functions by Modification and Editing. Springer-Verlag; Berlin Heidelberg: 2005. p. 141-177.Topics in Current Genetics 12
- Desrosiers R, Friderici K, Rottman F. Proc Natl Acad Sci U S A. 1974; 71:3971–3975. [PubMed: 4372599]
- 3. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG, He C. Nat Chem Biol. 2011; 7:885–887. [PubMed: 22002720]
- 4. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JRB, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJF, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CNA, Doney ASF, Morris AD, Smith GD, Hattersley AT, McCarthy MI. Science. 2007; 316:889–894. [PubMed: 17434869]
- Gerken T, Girard CA, Tung YCL, Webby CJ, Saudek V, Hewitson KS, Yeo GSH, McDonough MA, Cunliffe S, McNeill LA, Galvanovskis J, Rorsman P, Robins P, Prieur X, Coll AP, Ma M, Jovanovic Z, Farooqi IS, Sedgwick B, Barroso I, Lindahl T, Ponting CP, Ashcroft FM, O'Rahilly S, Schofield CJ. Science. 2007; 318:1469–1472. [PubMed: 17991826]
- Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, Brüning JC, Rüther U. Nature. 2009; 458:894–898. [PubMed: 19234441]
- Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vågbø CB, Shi Y, Wang WL, Song SH, Lu Z, Bosmans RPG, Dai Q, Hao YJ, Yang X, Zhao WM, Tong WM, Wang XJ, Bogdan F, Furu K, Fu Y, Jia G, Zhao X, Liu J, Krokan HE, Klungland A, Yang YG, He C. Mol Cell. 2013; 49:18–29. [PubMed: 23177736]
- 8. Bachellerie J, Amalric F, Caboche M. Nucleic Acids Res. 1978; 5:2927-2944. [PubMed: 693324]
- 9. Stoltzfus CM, Dane RW. J Virol. 1982; 32:918–931. [PubMed: 6285005]

- Camper SA, Albers RJ, Coward JK, Rottman FM. Mol Cell Biol. 1984; 4:538–543. [PubMed: 6201720]
- 12. Carroll SM, Narayan P, Rottman FM. Mol Cell Biol. 1990; 10:4456–4465. [PubMed: 2388614]
- 13. Schibler U, Kelley DE, Perry RP. J Mol Biol. 1977; 115:695-714. [PubMed: 592376]
- 14. Wei C, Moss B. Biochemistry. 1977; 16:1672–1676. [PubMed: 856255]
- 15. Dimock K, Stoltzfus CM. Biochemistry. 1977; 16:471-478. [PubMed: 189800]
- Canaani D, Kahana C, Lavi S, Groner Y. Nucleic Acids Res. 1979; 6:2879–2899. [PubMed: 223130]
- 17. Nichols JL, Welder L. Plant Sci Lett. 1981; 21:75-81.
- Narayan P, Ludwiczak RL, Goodwin EC, Rottman FM. Nucleic Acids Res. 1994; 22:419–426. [PubMed: 8127679]
- 19. Beemon K, Keith J. J Mol Biol. 1977; 113:165–179. [PubMed: 196091]
- 20. Kane SE, Beemon K. Mol Cell Biol. 1985; 5:2298-2306. [PubMed: 3016525]
- 21. Csepany T, Lin A, Baldick CJ, Beemon K. J Biol Chem. 1990; 265:20117–20122. [PubMed: 2173695]
- Horowitz S, Horowitz A, Nilsen TW, Munns TW, Rottman FM. Proc Natl Acad Sci U S A. 1984; 81:5667–5671. [PubMed: 6592581]
- 23. Narayan P, Rottman FM. Science. 1988; 242:1159-1162. [PubMed: 3187541]
- Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, Sorek R, Rechavi G. Nature. 2012; 485:201– 206. [PubMed: 22575960]
- 25. Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Cell. 2012; 149:1635–1646. [PubMed: 22608085]
- 26. Liu N, Parisien M, Dai Q, Zheng G, He C, Pan T. RNA. 2013 published online in advance of print.
- 27. Flusberg BA, Webster DR, Lee JH, Travers KJ, Olivares EC, Clark TA, Korlach J, Turner SW. Nat Methods. 2010; 7:461–465. [PubMed: 20453866]
- Vilfan ID, Tsai YC, Clark TA, Wegener J, Dai Q, Yi C, Pan T, Turner SW, Korlach J. J Nanobiotechnology. 2013; 11:8. [PubMed: 23552456]
- 29. Dai Q, Fong R, Saikia M, Stephenson D, Yu Y, Pan T, Piccirilli JA. Nucleic Acids Res. 2007; 35:6322–6329. [PubMed: 17881375]
- 30. Myers TW, Gelfand DH. Biochemistry. 1991; 30:7661-7666. [PubMed: 1714296]
- 31. Hillebrand GG, Beattie KL. Nucleic Acids Res. 1984; 12:3173–3184. [PubMed: 6371712]
- 32. Batista PJ, Chang H. unpublished data.
- Goodman MF, Creighton S, Bloom LB, Petruska J. Crit Rev Biochem Mol Biol. 1993; 28:83–126. [PubMed: 8485987]
- 34. Maden BEH. Prog Nucleic Acid Res Mol Biol. 1990; 39:241-303. [PubMed: 2247610]
- 35. Maden BEH. J Mol Biol. 1986; 189:681-699. [PubMed: 3783688]
- 36. Maden BEH. J Mol Biol. 1988; 201:289-314. [PubMed: 3418702]



Figure 1.

Screen of polymerase selectivity for incorporation of dTTP opposite A or m^6A in an RNA template. (A) Sequences of RNA template/DNA primer used in screen. (B) Autoradiogram showing primer extension (p+1 band) in the presence of A or m^6A . Products were resolved on a 20% polyacrylamide denaturing gel using a ³²P-5'-labeled primer.



Figure 2.

T insertion is correlated to the relative amount of m^6A at target position. AGXCUGCCACAUGCUGCA CAGUGC was used as the template RNA at 1 3M concentration with varied ratios of m^6A :A at the target position. Error bars show standard deviations from 5 trials.



Figure 3.

Identification of methylated adenine sites in human ribosomal RNA. Primers were designed to probe for m^6A at three sites in rRNA. Incorporation at these sites by *Tth* pol was compared to incorporation by *Tth* pol at known non-methylated control sites and to incorporation by nonselective AMV RT.



Figure 4.

Identification of the m⁶A site in the *bPRL* 3'-UTR. Incorporation of dTTP with *in vitro* transcribed (IVT) RNA was compared to incorporation templated by cellular *bPRL* RNA to differentiate the site of methylation. Incorporation with nonselective AMV RT is shown as an additional control.

Table 1

Steady-state incorporation efficiency for insertion of dTTP opposite A or m⁶A in synthetic RNAs by *Tth* DNA pol in varied sequence contexts.

sequence context	efficiency, X=A (V _{max} /K _m)	efficiency, X=m ⁶ A (V _{max} /K _m)	ratio
UXC	0.86±0.17	0.10±0.04	8.6
GXC	0.58±0.15	0.14±0.03	4.0
(G)GXC	1.22±0.17	0.19 ± 0.04	6.4
GXU	0.95±0.61	0.10 ± 0.10	9.1
CXU	1.13±0.77	0.14 ± 0.14	8.2
CXG	1.39±0.26	0.13±0.03	10.4
AXG	1.51±0.61	0.10 ± 0.02	15.6
AXA	1.87±1.25	0.11±0.06	17.5
(G)AXC	1.24±0.32	0.10 ± 0.05	13.1
UXA	3.52±0.94	0.33±0.22	10.6